Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Arkansas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Arkansas, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 84 Florida 69 Colorado 41 Texas 40 Massachusetts 38
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Arkansas

16 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-11-03
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
Pfizer
Phase 3
1,035
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-01-06
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
Stemline Therapeutics, Inc.
Phase 3
4,220
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-09-27
Recruiting
BostonGene and Exigent Genomic INsight Study
NCT06272864Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
BostonGene
Observational
400
Arkansas, California, Indiana, New Mexico, Oklahoma, Texas, Washington
2024-04-08
Active, closed
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837Breast Cancer
Pfizer
Phase 1/2
71
Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas
2024-02-19
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-11-14
Active, closed
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT05563220Breast Cancer, Metastatic Breast Cancer
Stemline Therapeutics, Inc.
Phase 1/2
435
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-01-24
Active, closed
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886Breast Cancer
Celcuity Inc
Phase 3
701
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2022-12-08
Active, closed
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585Breast Cancer
AstraZeneca
Phase 3
1,174
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2022-11-28
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
AstraZeneca
Phase 3
927
Arkansas, California, Connecticut, Indiana, Kentucky, Louisiana, Minnesota, Nevada
2021-10-25
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
Eli Lilly and Company
Phase 1
379
Arizona, Arkansas, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2019-12-10
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
Eli Lilly and Company
Phase 3
5,637
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2017-07-12
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
NCT02779751Non Small Cell Lung Cancer, Breast Cancer
Eli Lilly and Company
Phase 1
100
Arkansas, California, Colorado, Massachusetts, Michigan, New York
2016-11-14
Active, closed
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621Breast Cancer
Eli Lilly and Company
Phase 3
493
Arizona, Arkansas, California, Florida, Georgia, Minnesota, Nebraska, Nevada
2014-11-06
Active, closed
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02032823Breast Cancer
AstraZeneca
Phase 3
1,837
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2014-04-22
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/arkansas

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies with a site in Arkansas that also match the filters currently applied.

How many clinical trials are recruiting in Arkansas?

4 of the 16 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Arkansas), 16 studies
PhaseStudiesRecruitingShare
Phase 311368.8%
Phase 12012.5%
Phase 1/22012.5%
Observational116.3%

Most active sponsors

Lead sponsors with the most studies (Arkansas)
Lead sponsorStudiesRecruiting
AstraZeneca51
Eli Lilly and Company40
Pfizer20
Stemline Therapeutics, Inc.21
BostonGene11
Celcuity Inc10
Olema Pharmaceuticals, Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.